MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Prepaid expenses
Amortization of right-of-use ass...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss for the period
Lease liabilities
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss for the period
-3,150,228
-3,073,118
-954,059
-197,929
Amortization of right-of-use assets
35,041
34,294
15,439
29,663
Interest expense
-
-
-
-4,447
Stock-based compensation expense
9,792
-
-
-
Prepaid expenses
-2,179,230
-2,332,744
8,580,932
5,110
Lease liabilities
-35,698
-40,860
-15,302
-29,048
Accounts payable
5,978
-112,063
114,220
-4,731
Interest payable
-
-
-
4,447
Accrued expenses
1,325
1,599
5,294
-4,553
Other current assets
-
-
-
228,321
Net cash used in operating activities
-954,560
-857,404
-9,187,019
-440,029
Issuance of common stock
-
-
-
0
Issuance of preferred stock
-
-
-
0
Proceeds from issuance of common stock, net of underwriting costs - ipo
-
0
15,655,192
-
Loan from shareholders
-
-
-
400,000
Payment of offering costs
-
0
346,497
-
Net cash provided by financing activities
-
0
14,908,695
400,000
Net increase (decrease) in cash
-954,560
-857,403
5,681,646
-
Cash at beginning of period
4,973,134
5,830,537
148,891
-
Net increase (decrease) in cash
-
-
-
-40,029
Cash at end of period
4,018,574
4,973,134
5,830,537
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash
-$954,560
Prepaid expenses
-$2,179,230
Amortization of right-of-use
assets
$35,041
Stock-based compensation
expense
$9,792
Accounts payable
$5,978
Accrued expenses
$1,325
Net cash used in
operating activities
-$954,560
Canceled cashflow
$2,231,366
Net loss for the
period
-$3,150,228
Lease liabilities
-$35,698
Buy us a coffee
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)